Standout Papers

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metas... 2011 2026 2016 2021 853
  1. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma (2011)
    David H. Henry, Luís Costa et al. Journal of Clinical Oncology
  2. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial (2012)
    Jaafar Bennouna, Javier Sastre et al. The Lancet Oncology

Immediate Impact

4 by Nobel laureates 19 from Science/Nature 62 standout
Sub-graph 1 of 18

Citing Papers

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
2025 Standout
Colorectal cancer
2024 Standout
5 intermediate papers

Works of Roger von Moos being referenced

Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study
2014
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
2012 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Roger von Moos 4079 1835 1121 1348 232 6.0k
Aristotelis Bamias 2984 2184 1875 1600 274 6.7k
Shunji Takahashi 5147 2319 878 1276 350 7.6k
Rossana Berardi 4061 2725 1094 1836 342 7.1k
Penella J. Woll 4879 2956 822 1856 166 7.7k
Gary Richardson 2574 1212 464 723 103 3.7k
Luís Costa 3824 1507 907 1432 179 5.5k
Sandy Srinivas 2871 3340 2113 1929 191 6.3k
Guenther G. Steger 4434 1433 593 1260 155 5.8k
G.H. Blijham 2314 1166 1034 1044 88 4.6k
Judith R. Kroep 3003 1770 678 1549 213 6.8k

All Works

Loading papers...

Rankless by CCL
2026